Generic alternatives for brand drugs by spending proportion Canada 2018

This statistic shows the branded drugs for which generic alternatives were made available in Canada in 2018, by proportion of total spending. For the brand name drug Coversyl Plus, the generic alternative perindopril/indapamide was made available and made up 0.71 percent of the total drug spending in 2018.

Branded drugs for which generic alternatives were made available in Canada in 2018, by proportion of total drug spending

Generic name (Brand name)	Percentage of total spending
Perindopril/indapamide (Coversyl Plus)	0.71%
Aripiprazole (Abilify)	0.4%
Dabigatran (Pradaxa)	0.12%
Lacosamide (Vimpat)	0.08%
Alitretinoin (Toctino)	0.06%
Telmisartan/amlodipine beslate (Twynsta)	0.06%
Clobetasol (Clobex Spray)	0.04%
Budesonide (Entocort)	0.04%
Fosfomycin tromethamine (Monuro)	0.03%
Lansoprazole/amoxicilline/clarithromycine (HpPAC)	0.03%
Vardenafil (Levitra)	0.02%
Ambrisetan (Volibris)	0.02%
Dipyridamole/acetylsalicylic acid (Aggrenox)	0.01%
Atovaquone (Mepron)*	0.01%
Perindopril (Coversyl)	0%
Lamivudine oral liquid (3-TC)*	0%
Mupirocin (Bactroban Cream)	0%
Triamcinolone hexacetonide injection (Aristopan)	0%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2019

More information

Region

Canada

Survey time period

2018

Supplementary notes

Spending: Total cost of eligible prescription drugs, including the plan member’s portion as well as the plan sponsor’s portion net of any Product Listing Agreement discounts.
Traditional drugs: Medications that are easy to self-administer and require less intensive clinical monitoring, such as those used to treat diabetes and high blood pressure.
* Specialty drugs: Medications used to treat chronic, complex conditions such as severe rheumatoid arthritis, multiple sclerosis and cancer. Includes injectable and non-injectable drugs and have one or more of the following qualities: frequent dosing adjustments and intensive clinical monitoring; intensive patient training and compliance assistance; limited distribution; and/or specialized handling or administration.

Citation formats